NanoLogix Presents Hydrogen Production Technologies at Penwest Renewable Energy Convention in Las Vegas

SHARON, PA -- (MARKET WIRE) -- March 7, 2007 -- NanoLogix, Inc. (PINKSHEETS: NNLX) is pleased to announce its participation at the Penwest Renewable Energy Conference in Las Vegas on March 7 and 8.

Dana Allen, Member of the Board of Directors and VP of Strategic Partnering, representing NanoLogix at the convention, stated, "This is a premier event in the industry with attendance in the thousands. The attendance this year is approximately double last year's, all of which indicates the explosive growth in this industry. We are discussing the advantages of generating Hydrogen from biomass and biowaste using NanoLogix patented technologies, instead of using the traditional energy wasting methods requiring natural gas or electrical power." Mr. Allen may be contacted at the event by calling 650-743-7111.

NanoLogix will be presenting at The National Hydrogen Conference in Houston in April. Dr. Harry Diz will be presenting a scientific paper, Paper #3306 "Microbial Production of Hydrogen from Sugar-rich Wastewater," at the conference regarding the NanoLogix Hydrogen Bioreactor currently operating at the Welch Foods plant in Pennsylvania. Additional information regarding booth and presentation times will be issued prior to the conference.

Dr. Diz's scientific paper regarding the NanoLogix hydrogen test site at Welch's concluded with the following excerpt, "Hydrogen production was sustained over more than six months of operation while methane production was controlled and limited. This experience confirmed the ability to maintain a hydrogen-generating culture in an industrial setting over an extended period of time."

About NanoLogix, Inc.:

NanoLogix is an industry innovator in the research, development and commercialization of nano-biotechnologies, applications and processes. The Company owns or has the rights to 32 patented technologies. The Company is currently focused on the production of hydrogen from agricultural feedstock, industrial wastewater and municipal waste streams to create new sources of energy. NanoLogix is presently operating a hydrogen bioreactor at Welch's Food and has recently signed an agreement with the City of Erie Wastewater Treatment Plant for a prototype bioreactor installation. Additionally, NanoLogix develops and markets diagnostic test kits for use in early detection of infectious human diseases such as cancer, cystic fibrosis and AIDS, and owns a patent for the non-toxic induction of apoptosis ('cell suicide') for the treatment of cancer. For more information on the Company, visit http://www.nanologix.net.

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact Information: Contacts: Investor Relations Andrew Barwicki 516.662.9461 Website: www.nanologix.net